Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 871 to 880 of 2733 total matches.

In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2026  (Issue 1750)
in chronic HF or chronic kidney disease.1 Furosemide has been available for years in oral and IV ...
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix, is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.
Med Lett Drugs Ther. 2026 Mar 16;68(1750):47-8   doi:10.58347/tml.2026.1750d |  Show IntroductionHide Introduction

In Brief: Two Intranasal Corticosteroid HFA Aerosols for Allergic Rhinitis (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 15, 2012  (Issue 1401)
formulations may be better tolerated. Table 1. Beclomethasone and Ciclesonide for Treatment of Allergic ...
The FDA has approved 2 intranasal HFA (hydrofluoroalkane) aerosols of the corticosteroids beclomethasone dipropionate (Qnasl – Teva Respiratory) and ciclesonide (Zetonna – Sunovion) for once-daily treatment of seasonal and perennial allergic rhinitis. They are the first HFA nasal steroids to become available in the US (HFA propellants do not deplete the ozone layer). Both drugs are already available for these indications as aqueous nasal sprays. Aqueous ("wet") formulations can cause adverse effects such as postnasal drip, moist feeling in the nose, strong odor, and bitter aftertaste,...
Med Lett Drugs Ther. 2012 Oct 15;54(1401):84 |  Show IntroductionHide Introduction

Elderberry for Influenza

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
strains in vitro.1-3 In two small studies (conducted outside the US), adults with influenza A or B virus ...
Patients may ask about taking elderberry for prevention and treatment of influenza. Products containing elderberry are promoted for relief of cold and flu symptoms and as an immune system booster.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):32 |  Show IntroductionHide Introduction

OTC Differin Epiduo Gel for Acne

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2026  (Issue 1759)
gel (Galderma), a fixed-dose combination of the synthetic retinoid adapalene 0.1% and the oxidizing ...
Differin Epiduo gel (Galderma), a fixed-dose combination of the synthetic retinoid adapalene 0.1% and the oxidizing agent benzoyl peroxide 2.5%, is now available over the counter (OTC) for topical treatment of acne in patients ≥12 years old. It will remain available by prescription for use in patients 9-11 years old. A gel containing adapalene 0.3% and benzoyl peroxide 2.5% (Epiduo Forte, and generics) is available by prescription for use in patients ≥12 years old.
Med Lett Drugs Ther. 2026 Jul 20;68(1759):116   doi:10.58347/tml.2026.1759d |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently.1 Treatment ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023  (Issue 1684)
, more than in any previous year.1 Several guidelines on the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44   doi:10.58347/tml.2023.1684a |  Show IntroductionHide Introduction

In Brief: New Warning for OTC Orlistat (Alli)

   
The Medical Letter on Drugs and Therapeutics • Jul 20, 2026  (Issue 1759)
loss.1 The label for the 120-mg capsules, which are available by prescription as Xenical,2 already ...
The FDA now requires a warning about a risk of acute kidney injury in the product label for the 60-mg capsules of the pancreatic and gastric lipase inhibitor orlistat, which are available over the counter as Alli for weight loss.1 The label for the 120-mg capsules, which are available by prescription as Xenical, already includes a warning about a risk of oxalate nephrolithiasis and oxalate nephropathy (orlistat increases oxalate absorption).
Med Lett Drugs Ther. 2026 Jul 20;68(1759):116   doi:10.58347/tml.2026.1759c |  Show IntroductionHide Introduction

Antiviral Drugs for Seasonal Influenza

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2026  (Issue 1767)
, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces ...
Influenza is typically a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated with influenza illness. Annual vaccination should be offered to all persons ≥6 months old as long as influenza viruses are circulating in the community.
Med Lett Drugs Ther. 2026 Nov 9;68(1767):177-81   doi:10.58347/tml.2026.1767a |  Show IntroductionHide Introduction

Teduglutide Injection (Gattex) for Short Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2013  (Issue 1414)
and often experience diarrhea, weight loss, malnutrition and dehydration.1 SBS is the most common diagnosis ...
The FDA has approved teduglutide (te due’ gloo tide; Gattex – NPS), a recombinant DNA analog of glucagon-like peptide-2 (GLP-2), for treatment of short bowel syndrome (SBS) in adults who are dependent on parenteral support.
Med Lett Drugs Ther. 2013 Apr 15;55(1414):29-30 |  Show IntroductionHide Introduction

Drugs for MRSA Skin and Soft-Tissue Infections

   
The Medical Letter on Drugs and Therapeutics • May 12, 2014  (Issue 1442)
of the US.1,2 Community-associated MRSA usually causes furunculosis, purulent cellulitis, and abscesses ...
Methicillin-resistant Staphylococcus aureus (MRSA), which was traditionally a nosocomially-acquired organism but now frequently occurs in the absence of healthcare exposure, is the predominant cause of suppurative skin and soft-tissue infections in many parts of the US. Community-associated MRSA usually causes furunculosis, purulent cellulitis, and abscesses, but necrotizing fasciitis, necrotizing pneumonia, and sepsis can also occur.
Med Lett Drugs Ther. 2014 May 12;56(1442):39-40 |  Show IntroductionHide Introduction